Self-Nanoemulsifying Drug Delivery System for Atorvastatin Calcium: Design, Optimization and Evaluation
Abstract
Atorvastatin calcium (ATC) is the choice of drug in the treatment of moderate to severe hypercholesterolemia. In the current study, ATC self-nanoemulsifying drug delivery systems (SNEDDS) were prepared in an attempt to improve the bioavailability by enhancing its solubility. The solubility of ATC in various oils, surfactants, and co-surfactants were determined. Based on their solubility, Capmul MCM (oil), Tween 20 (surfactant), propylene glycol (Co-surfactant) was selected for preparation of SNEDDS. Self-nanoemulsification region were determined by pseudo-ternary phase diagrams. The compatibility of drug with excipients were determined by FTIR spectroscopy and Optimized SNEDDS were evaluated for thermodynamic stability, dispersibility, robustness to dilution, particle size measurements, refractive index, percent transmittance, drug content, In vitro drug release etc. The SNEDDS were successfully formulated with the selected excipients. FTIR studies confirm there is no significant interaction between drug and excipients. The metastable formulations were ruled out by thermodynamic tests and robust to dilution test. The optimized ATC SNEDDS yielded nano-emulsion of mean globule size 42.21 nm. In vitro release studies shows that all the SNEDDS released more than 90% of drug at the end of 30 min, whereas the pure drug shows only the release of 29.54% at 30 min. The optimized formulation was subjected to various conditions of storage as per ICH guidelines for 3 months. ATC SNEDDS successfully withstood the stability testing. Thus this study indicates that the SNEDDS can be used as a potential drug carrier for solubility enhancement thereby drug release of ATC and other lipophilic drugs.
Keywords: Self-nanoemulsifying drug delivery systems, Pseudo-ternary phase diagrams, Thermodynamic stability
Cite this Article
Panner Selvam R, Parthasarathi K Kulkarni, Mudit Dixit, Self-Nanoemulsifying Drug Delivery System for Atorvastatin Calcium: Design, Optimization and Evaluation, Research & Reviews: A Journal of Drug Design & Discovery, 2015; 2(2): 27–36p.
Downloads
Published
Issue
Section
License
Copyright Transfer and Declaration Form (Please compile this form, sign and send by e-mail and post)
Journal Title:
Title of the Paper:
Corresponding Author’s Information: Name: Address:
E-mail:
Contact Number: I
t is herein agreed that: The copyright to the above-listed unpublished and original article is transferred to STM Journals. This copyright transfer covers the exclusive right to reproduce and distribute the contribution, including reprints, translations, photographic reproductions, microform, electronic form (offline, online), or any other reproductions of similar nature. I/We declare that above manuscript is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere. I/ We warrant(s) that his/her/their contribution is original, except for such excerpts from copyrighted works as may be included with the permission of the copyright holder and author thereof, that it contains no libelous statements, and does not infringe on any copyright, trademark, patent, statutory right, or propriety right of others. I/We will not publish his/her/their above said contribution anywhere else without the prior written permission of the publisher unless it has been changed substantially.I/We also agree to the authorship of the article in the following order:Author(s) Name Signature(s)1. ________________2. ________________3. ________________4. ________________The author(s) agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal (comments if any to the editor can be added below).
